Literature DB >> 16369399

Hepatitis B virus infection in liver transplant candidates and recipients.

Patrick Yachimski1, Raymond T Chung.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16369399      PMCID： PMC1681606     

Source DB:  PubMed          Journal:  MedGenMed        ISSN： 1531-0132


× No keyword cloud information.
  74 in total

1.  Sanctuary of hepatitis B virus in bone-marrow cells of patients undergoing liver transplantation.

Authors:  Y Ilan; E Galun; A Nagler; Y Baruch; N Livni; R Tur-Kaspa
Journal:  Liver Transpl Surg       Date:  1996-05

2.  Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation.

Authors:  K W Lee; D S Lee; H H Lee; S J Kim; J W Joh; J M Seo; Y H Choe; S K Lee
Journal:  Transplant Proc       Date:  2004-10       Impact factor: 1.066

3.  Can hepatitis B core antibody positive livers be used safely for transplantation: hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody positive.

Authors:  D H Van Thiel; N De Maria; A Colantoni; L Friedlander
Journal:  Transplantation       Date:  1999-08-27       Impact factor: 4.939

4.  Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants.

Authors:  S Uemoto; K Sugiyama; H Marusawa; Y Inomata; K Asonuma; H Egawa; T Kiuchi; Y Miyake; K Tanaka; T Chiba
Journal:  Transplantation       Date:  1998-02-27       Impact factor: 4.939

5.  Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.

Authors:  X Xiong; C Flores; H Yang; J J Toole; C S Gibbs
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

6.  The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV.

Authors:  Heidi Hannon; Corinne Isnard Bagnis; Yves Benhamou; Hélène Beaufils; Mark Sullivan; Carol Brosgart; Hassan Izzedine; Thierry Poynard; Gilbert Deray
Journal:  Nephrol Dial Transplant       Date:  2004-02       Impact factor: 5.992

7.  Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.

Authors:  N A Terrault; S Zhou; R W McCory; T L Pruett; J R Lake; J P Roberts; N L Ascher; T L Wright
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

8.  Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.

Authors:  J S Markowitz; P Martin; A J Conrad; J F Markmann; P Seu; H Yersiz; J A Goss; P Schmidt; A Pakrasi; L Artinian; N G Murray; D K Imagawa; C Holt; L I Goldstein; R Stribling; R W Busuttil
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

9.  Treatment of fibrosing cholestatic hepatitis with lamivudine.

Authors:  T M Chan; P C Wu; F K Li; C L Lai; I K Cheng; K N Lai
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

10.  Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.

Authors:  Lluís Castells; Víctor Vargas; Francisco Rodríguez; Helena Allende; Maria Buti; José F Sánchez-Avila; Rosendo Jardí; Carlos Margarit; Tomás Pumarola; Rafael Esteban; Jaime Guardia
Journal:  Liver Transpl       Date:  2002-10       Impact factor: 5.799
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.